Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
NCT07275814Phase 3Completed
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HRS-9231 in Central nervous system lesion (2 arms). Primary endpoints: Lesion visualization score (border delineation) at Day 1, Lesion visualization score (internal morphology) at Day 1 and 1 more. Started Nov 2025; status: completed.
02
Drugs
HRS-9231
03
Conditions
Central nervous system lesion
Beyond the preview
Go deeper on NCT07275814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275814.